Accelerated atherosclerosis and inflammation in systemic lupus erythematosus

Japanese Journal of Clinical Immunology

Volumn 35, Issue 6, 2012, Pages 470-480

  Asanuma, Yu Funakubo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

atherosclerosis; cardiovascular disease; inflammation; systemic lupus erythematosus

Indexed keywords

EID: 84938950594     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.35.470     Document Type: Article

References (67)

1. Ward M. M., Pyun E., Studenski S. : Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum. 38 : 1492–1499, 1995.
2. Aranow C., Ginzler E. M. : Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 9 : 166–169, 2000 ;
3. Abu-Shakra M., Urowitz M. B., Gladman D. D., Gough J. Mortality studied in systemic lupus erythematosus. Results from a single center. I. Cause of death. J Rheumatol. 22 : 1259–1264, 1995.
4. Urowitz M. B., et al. : The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 60 : 221–225, 1976.
5. Nossent J., et al. : Current causes of death in systemic lupus erythematosus in Europe, 2000–2004 : Relation to disease activity and damage accrual. Lupus. 16 : 309–317, 2007.
6. Hak A. E., et al. : Systemic lupus erythematosus and risk of cardiovascular disease results from the Nurses' Health Study. Arthritis rheum. 61: 1396–1402, 2009.
7. Manzi S., et al. : Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol. 145 : 408–415, 1997.
8. Benqtsson C., et al. : Cardiovascular event in systemic lupus erythematosus in northern Sweden : Incidence and predictors in a 7-year followup study. Lupus. 21: 452–459, 2012.
9. Esdaile J. M., et al. : Traditional Framingham risk scores fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis rheum. 44 : 2331–2337, 2001.
10. Asanuma Y., et al. : Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 349 : 2307–2315, 2003.
11. Roman M. J., et al. : Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N EnglJ Med. 349 : 2399–2406, 2003.
12. Kiani A. N., Magder L. S., Petri M. : Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol. 35 : 1300–1306, 2008.
13. Kiani A. N., et al. : Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology. 50 : 2071–2079, 2011.
14. Bruce I. N., et al. : Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol. 27 : 2372–2377, 2000.
15. Nikpour M., et al. : Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. J Rheumatol. 36 : 288–294, 2009.
16. Symmons D. P., Gabriel S. E. : Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 7: 399–408, 2011.
17. Petri M., et al. : Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 93 : 513–519, 1992.
18. Manzi S., et al. : Age-specific incidence rates of myocardial infarction and angina in women with Systemic Lupus Erythematosus : Comparison with the Framingham study. Am J Epidimiol. 145 : 408–415, 1997.
19. Toloza S. M., et al. : Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis rheum. 50 : 3947–3957, 2004.
20. Urowitz M. B., et al. : Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythrmatosus. Arthritis Care Res. 62 : 881–887, 2010.
21. Bertoli A. M., et al. : Factors associated with arterial vascular events in PROFILE: A multiethnic lupus cohort. Lupus. 18 : 958–965, 2009.
22. Urowitz M. B., Ibanez D., Gladman D. D. : Atherosclerotic vascular events in a single large lupus cohort: Prevalence and risk factors. J Rheumatol. 34 : 329–354, 2007.
23. Chung C. P., et al. : Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J Rheumatol. 34 : 1849–1854, 2007.
24. Bruce I. N., et al. : Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 26 : 2137–4317, 1999.
25. Kawai S., Mizushima Y., Kaburaki J. : Increased serum lipoprotein (a) levels in systemic lupus erythematosus with myocardial and cerebral infarctions. J Rheumatol. 22 : 1210–1211, 1995.
26. Bulkley B. H., Roberts W. C. : The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy : A study of 36 necropsy patients. Am J Med. 58 : 243–264, 1975.
27. Bulkley B. H., Klacsmann P. G., Hutchins G. M. : Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: A clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J. 59: 563–569, 1978.
28. Asanuma Y., Kawai S : Apolipoprotein (a) deposition in atherosclerotic coronary arteries of a patient with systemic lupus erythematosus : Comment on the article by Romero et al. Arthritis rheum. 43 : 2141–2142, 2000.
29. Chung C. P., et al. : High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 66 : 208–214, 2007.
30. Chung C. P., et al. : Inflammation-associated insulin resistance. Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis rheum. 58: 2105–2108, 2008.
31. Ross R. : Atherosclerosis—an inflammatory disease. N Engl J Med 340 : 115–124, 1999.
32. Kao A. H., Sabatine J. M., Manzi S. : Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol. 15 : 519–527, 2003.
33. Erbel C., et al. : Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol. 102 : 123–132, 2007.
34. Von Feldt J. M., et al. : Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis rheum. 54: 2220–2227, 2006.
35. Karp I., et al. : Recent corticosteroid use and recent disease activity : Independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis rheum. 59 : 169–175, 2008.
36. Asanuma Y., et al. : Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: Relationship to cardiovascular risk factors. J Rheumatol. 33 : 539–545, 2006.
37. Mak A., Liu Y., Ho R. C. : Endothelium-dependent but not endothelium-independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: A metaanalysis and metaregression. J Rheumatol. 38 : 1296–1303, 2011.
38. Kim T., et al. : Serum levels of interferons in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 70 : 562–569, 1987.
39. Skaggs B. J., Hahn B. H., McMahon M. : Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol. 8 : 214–223, 2012.
40. Sturfelt G., et al. : Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis rheum. 30 : 382–388, 1987.
41. Boey M. L., et al. : Thrombosis in systemic lupus erythematosus: Striking association with the presence of circulating lupus anticoagulant. Br Med J. 287 : 1021–1023, 1983.
42. Harris E. N., et al. : Anticardiolipin antibodies : Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Luncet. 2 : 1211–1214, 1983.
43. Nicolo D., Monestier M. : Antiphospholipid antibodies and atherosclerosis. Clinical Immunology. 112 :183–189, 2004.
44. Nicolo D., Goldman B. I., Monestier M. : Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis rheum. 48 : 2974–2978, 2003.
45. Farzaneh-Far A., et al. : Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis rheum. 54 : 3918–3925, 2006.
46. Fesmire J., Wolfson-Reichlin M., Reichlin M. : Effects of autoimmune antibodies anti-lipoprotein lipase, anti-low density lipoprotein, and anti-oxidized low density lipoprotein on lipid metabolism and atherosclerosis in systemic lupus erythematosus. Rev Bras Reumatol. 50 : 539–551, 2010.
47. Dinu A. R., et al. : Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. 7: 355–360, 1998.
48. Petri M., et al. : Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med. 96 : 254–259, 1994.
49. Petri M., et al. : Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 93 : 513–519, 1992.
50. Kiani A. N., Magder L. S., Petri M. : Mycopheno-late mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int., Jul 27, 2011. [Epub ahead of print].
51. Haque S., et al. : Risk factors for clinical coronary heart disease in systemic lupus erythematosus : The lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol. 37 : 322–329, 2010.
52. Toloza S. M., et al. : LUMINA Study Group. : Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis rheum. 50: 3947–3957, 2004.
53. Schanberg L. E., et al. : Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. : Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis rheum. 60: 1496–1507, 2009.
54. Major A. S., Fazio S., Linton M. F. : B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 22 : 1892–1898, 2002.
55. Caligiuri G., et al. : Protective immunity against atherosclerosis carried by B cells of hyper-cholesterolemic mice. J Clin Invest. 109 : 745–753, 2002.
56. Ait-Oufella H., et al. : B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 207 : 1579–1587, 2010.
57. Pego-Reigosa J. M., et al. : Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy : A retrospective observational study. Rheumatology (Oxford). 49 : 691–696, 2010.
58. Amuro H., et al. : Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis rheum. 2073–2085, 2010.
59. McCarey D. W., et al. : Trial of Atorvastatin in Rheumatoid Arthritis (TARA) : Double-blind, randomised placebo-controlled trial. Lancet. 363: 2015–2021, 2004.
60. Petri M. A., et al. : Lupus atherosclerosis prevention study (LAPS). Ann Rheum Dis. 70 : 760–765, 2011.
61. Plazak W., et al. : Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients : A prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther. 13 : R117, 2011.
62. Schanberg L. E., et al. : Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis rheum. 64:285–296, 2012.
63. Marks D., et al. : A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 168 : 1–14, 2003.
64. Elliott J. R., Manzi S. : Cardiovascular risk assessment and treatment in systemic lupus er-thematosus. Best Pract Res Clin Rheumatol. 23: 481–494, 2009.
65. Peters M. J., et al. : EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 69 : 325–331, 2010.
66. Nikpour M., et al. : Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus : A prospective proof-of-concept cohort study. Arthritis Res Ther. 13 : R156, 2011.
67. Mok C. C., et al. : Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Arthritis Care Res. 63 : 875–883, 2011.